5 news items
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
INZY
23 May 24
. These statements include, but are not limited to, statements relating to the availability of data from clinical trials, and the potential benefits of INZ-701
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
INZY
7 May 24
clinical trials, the availability and timing of data from clinical trials, the potential benefits of INZ-701, our regulatory strategy, including our
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
INZY
8 Apr 24
treated with INZ-701 will translate to clinical benefits in a future trial in children." "The high risk of ischemic stroke in pediatric patients
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
INZY
26 Mar 24
and contents of our planned topline data update, the design of our planned clinical trials, and the potential benefits of INZ-701. The words
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
INZY
12 Mar 24
, the potential benefits of INZ-701, the expectations for the global patient registry and the sufficiency of the Company's cash resources. The words
- Prev
- 1
- Next